Introduction- Statins are drugs frequently prescribed in patients suffering from dyslipidaemia and, even, in patients with coronary artery disease, diabetes mellitus, stroke, blood hypertension, and chronic kidney disease with or without dyslipidaemia. Statins are molecules of fungal origin that, by inhibiting the hydroxymethylglutaryl-CoA (HMG-CoA) reductase enzyme, a key step in the sterol biosynthetic pathway, became powerful cholesterol-lowering medications. Areas Covered- In this review article, the post marketing surveillance of atorvastatin and rosuvastatin are discussed based on the analysis of electronic reports containing suspected adverse reactions associated with statins, submitted to Eudravigilance (EV), up to February 2024.